Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Psychiatry

Long-Term Management and Quality of Life

At a Glance

Tardive dyskinesia often persists, even after the triggering medication is reduced or stopped, although some people improve or enter remission. Long-term care combines symptom treatment, regular monitoring, and support for eating, speaking, dental health, social life, and emotional well-being.

Living with Tardive Dyskinesia (TD) is a long-term journey that affects your social life, your self-image, and your daily physical comfort. Because TD is often persistent, the goal of care shifts from a quick fix to long-term management and maintaining your overall quality of life [1][2].

Understanding the long-term outlook and how to effectively monitor your progress will help you stay engaged with your health.

The Long-Term Outlook: What to Expect

A common question after a TD diagnosis is whether the movements will ever go away. The answer varies significantly from person to person [3].

For many people, TD is a persistent condition. Even if the medication that caused it is reduced or stopped, the movements can last for years or become permanent [1][4].

  • Remission is Possible: In some observational studies, a portion of patients experienced a remission—a period where symptoms significantly decreased or disappeared over years [5]. However, remission rates depend heavily on the specific study population, the definition of remission, and whether the offending drug was stopped. These study estimates do not guarantee an individual prognosis.
  • Heterogeneity: Everyone’s experience is different. Some people find their movements stay stable, some see slow improvement, and others may have fluctuations [3][6].

Measuring What Matters: Function and Impact

While doctors use the AIMS scale to count and rate your movements, a low score doesn’t necessarily mean your life is unaffected. You might have “mild” movements that cause significant embarrassment or difficulty [7][8].

To capture your side of the story, some clinics use patient-reported tools like the Tardive Dyskinesia Impact Scale (TDIS) [7].

  • Patient-Reported Outcomes: The TDIS is a questionnaire focusing on how TD affects your physical functioning (eating, speaking) and your socioemotional well-being (feeling self-conscious, avoiding others) [7][9].
  • Shared Goals: Whether your clinic uses the TDIS or a simple conversation, assessing your daily function is critical. The meaning of any score change depends on your baseline, but the ultimate goal is to align your treatment with what matters most to you [10].

The Hidden Burden of TD

The impact of TD often extends far beyond the involuntary movements themselves, creating a burden on how you move through the world [2][11].

Social and Psychological Impact

Research highlights that many patients with TD feel it has a moderate-to-severe impact on their quality of life [12].

  • Stigma and Withdrawal: Many people experience stigma—the feeling of being judged in public [13]. This can lead to social withdrawal, avoiding dating, visiting friends, or attending events [9][13].
  • Daily Life: TD can affect how others perceive you, which may lead to challenges in professional settings [11][13].

Physical Challenges and Supportive Care

Visible movements can also affect internal muscles and structures. You may benefit from supportive care beyond medications:

  • Dental Care: Involuntary jaw and tongue movements can cause tooth wear or injury inside the mouth. Regular dental check-ups are vital.
  • Speech and Swallowing: If throat or chest muscles are involved, you may find it harder to swallow safely or speak clearly [14]. A speech-language pathologist can provide exercises and strategies to help.

Staying on Track: Long-Term Management

Because TD is chronic, staying consistent with your treatment plan is key.

The Role of VMAT2 Inhibitors

Medications like valbenazine and deutetrabenazine can provide sustained relief for many patients over years [15][16].

  • Sustained Benefit: In open-label extension studies, groups of patients taking these medications maintained significant improvements in their AIMS scores and reported quality-of-life benefits [15]. However, these are average group results from specific studies.
  • The “Washout” Effect: VMAT2 inhibitors control symptoms but do not cure the underlying brain changes. If you stop taking the medication, movements typically return. Never pause your VMAT2 inhibitor just to “test” for remission without a clinician’s plan [17][18].

Adherence and Self-Monitoring

Adherence means taking your medication exactly as prescribed. If side effects like sleepiness or issues with medication cost make this difficult, tell your care team [18][19].

  • Flexible Monitoring: Guidelines suggest structured monitoring for TD, but your follow-up schedule should be individualized based on your medication changes, symptom severity, side effects, and psychiatric stability [20][21].
  • Involve Your Support System: Family members and caregivers can notice subtle changes in your movements and provide vital emotional support [22][23].

By maintaining an open dialogue with your care team and exploring psychosocial or physical support options, you can manage the physical symptoms of TD while focusing on the social and emotional parts of your life that matter most.

Common questions in this guide

Will tardive dyskinesia ever go away?
Tardive dyskinesia can persist for years or become permanent, even after the medication that triggered it is reduced or stopped. Some people experience major improvement or remission, but the long-term outlook varies and cannot be predicted from the diagnosis alone.
How is tardive dyskinesia monitored over time?
Clinicians may use the AIMS scale to rate involuntary movements and compare results with an earlier baseline. They may also ask how symptoms affect eating, speaking, work, relationships, and emotional well-being, using a questionnaire such as the Tardive Dyskinesia Impact Scale when available.
Do valbenazine and deutetrabenazine cure tardive dyskinesia?
Valbenazine and deutetrabenazine can reduce tardive dyskinesia symptoms and may provide ongoing benefit while they are taken. They control symptoms rather than reverse the underlying brain changes, so movements often return after treatment is stopped; do not pause either medicine without a clinician's plan.
How can tardive dyskinesia affect daily life and mental well-being?
Visible movements may cause embarrassment, self-consciousness, stigma, or avoidance of social and professional activities. Changes in jaw, tongue, throat, or chest muscle movements can also interfere with eating, speaking, or swallowing.
When should I seek dental or swallowing support for tardive dyskinesia?
Regular dental visits are important if jaw or tongue movements cause tooth wear or injuries inside the mouth. A speech-language pathologist can assess speaking or swallowing problems and offer exercises and strategies to improve safety and function.
What should I do if TD medication causes sleepiness or is difficult to afford?
Tell your care team about sleepiness, cost problems, missed doses, or any other barrier to taking medication as prescribed. Your clinician can review options and personalize follow-up, but you should not change or stop treatment on your own.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Now that I’ve been on treatment for a while, how does my most recent structured assessment score compare to my baseline?
  2. 2.Do you use patient-reported questionnaires like the TDIS, or how else can we track how these movements affect my social life and work?
  3. 3.Based on my progress, what is the realistic long-term outlook for my specific symptoms?
  4. 4.How can we manage side effects like sleepiness so that I can stay consistent with my TD medication?
  5. 5.Should we consider a referral for a swallowing evaluation or dental exam to protect my physical health?
  6. 6.Are there local support groups, psychosocial resources, or occupational therapy options to help with the daily impact of TD?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Tardive Dyskinesia in Older Persons Taking Antipsychotics.

    Citrome L, Isaacson SH, Larson D, Kremens D

    Neuropsychiatric disease and treatment 2021; (17()):3127-3134 doi:10.2147/NDT.S328301.

    PMID: 34703232
  2. 2

    Patient and physician perceptions of the burden of tardive dyskinesia: an international survey.

    Chepke C, Levin AP, Yang A, et al.

    BMJ neurology open 2025; (7(2)):e001170 doi:10.1136/bmjno-2025-001170.

    PMID: 41368037
  3. 3

    Covert Dyskinesia With Aripiprazole: Tip of the Iceberg? A Case Report and Literature Review.

    Gomaa H, Mahgoub Y, Francis A

    Journal of clinical psychopharmacology 2021; (41(1)):67-70 doi:10.1097/JCP.0000000000001333.

    PMID: 33347026
  4. 4

    Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

    Gupta H, Moity AR, Jumonville A, et al.

    Health psychology research 2021; (9(1)):24929 doi:10.52965/001c.24929.

    PMID: 35106396
  5. 5

    The Outcome of Antipsychotics-induced Tardive Syndromes: A Ten-year Follow-up Study.

    Chou PC, Lee Y, Chang YY, et al.

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2023; (21(3)):488-498 doi:10.9758/cpn.22.1000.

    PMID: 37424417
  6. 6

    Reversible aripiprazole-induced tardive dyskinesia: a case series from Saudi Arabia and literature review.

    Alshahrani SM, Althagafi LM, Saeedi JA, et al.

    Frontiers in psychiatry 2026; (17()):1749247 doi:10.3389/fpsyt.2026.1749247.

    PMID: 41788644
  7. 7

    The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation.

    Farber RH, Stull DE, Witherspoon B, et al.

    Journal of patient-reported outcomes 2024; (8(1)):2 doi:10.1186/s41687-023-00679-4.

    PMID: 38175450
  8. 8

    Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.

    Tanner CM, Caroff SN, Cutler AJ, et al.

    Journal of patient-reported outcomes 2023; (7(1)):21 doi:10.1186/s41687-023-00551-5.

    PMID: 36892733
  9. 9

    Measuring What Matters: Further Validation for the Tardive Dyskinesia Impact Scale, a Novel Patient-Reported Outcome Measure in Valbenazine Clinical Trials.

    Bron M, Mathias SD, Stull DE, et al.

    The Journal of clinical psychiatry 2026; (87(2)).

    PMID: 42095693
  10. 10

    Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool.

    Bhidayasiri R, Kane JM, Frei KP, et al.

    Parkinsonism & related disorders 2020; (77()):141-145 doi:10.1016/j.parkreldis.2020.06.023.

    PMID: 32823151
  11. 11

    Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia.

    McEvoy J, Gandhi SK, Rizio AA, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2019; (28(12)):3303-3312 doi:10.1007/s11136-019-02269-8.

    PMID: 31435866
  12. 12

    RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.

    Caroff SN, Yeomans K, Lenderking WR, et al.

    Journal of clinical psychopharmacology 2020; (40(3)):259-268 doi:10.1097/JCP.0000000000001201.

    PMID: 32332461
  13. 13

    An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia.

    Ayyagari R, Goldschmidt D, Mu F, et al.

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2022; (20(1)):154-166 doi:10.9758/cpn.2022.20.1.154.

    PMID: 35078958
  14. 14

    Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.

    Sreeram V, Shagufta S, Kagadkar F

    Cureus 2019; (11(8)):e5471 doi:10.7759/cureus.5471.

    PMID: 31641566
  15. 15

    Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

    Hauser RA, Barkay H, Fernandez HH, et al.

    Frontiers in neurology 2022; (13()):773999 doi:10.3389/fneur.2022.773999.

    PMID: 35280262
  16. 16

    Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.

    Correll CU, Citrome L, Singer C, et al.

    Journal of clinical psychopharmacology 2024; (44(4)):353-361 doi:10.1097/JCP.0000000000001860.

    PMID: 38767901
  17. 17

    The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.

    Factor SA, Remington G, Comella CL, et al.

    The Journal of clinical psychiatry 2017; (78(9)):1344-1350.

    PMID: 29141124
  18. 18

    Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.

    Citrome L

    Expert review of neurotherapeutics 2018; (18(4)):323-332 doi:10.1080/14737175.2018.1455504.

    PMID: 29557243
  19. 19

    Real-World Experience With VMAT2 Inhibitors.

    Niemann N, Jankovic J

    Clinical neuropharmacology 2019; (42(2)):37-41 doi:10.1097/WNF.0000000000000326.

    PMID: 30870235
  20. 20

    Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel.

    El-Mallakh RS, Belnap A, Iyer S, et al.

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2023; (29(7)):1096-1104 doi:10.1089/tmj.2022.0234.

    PMID: 36520584
  21. 21

    Measurement-based Diagnosis and Treatment for Tardive Dyskinesia.

    Correll CU, Citrome L

    The Journal of clinical psychiatry 2021; (82(5)).

    PMID: 34464521
  22. 22

    Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.

    Jackson R, Brams MN, Citrome L, et al.

    Neuropsychiatric disease and treatment 2021; (17()):1589-1597 doi:10.2147/NDT.S310605.

    PMID: 34079257
  23. 23

    How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.

    McEvoy JP

    The Journal of clinical psychiatry 2020; (81(6)).

    PMID: 33147658

This page explains long-term management and quality-of-life issues in tardive dyskinesia for informational purposes only and does not constitute medical advice. Discuss medication changes, swallowing or dental concerns, and support options with your clinician.

Get notified when new evidence is published on Tardive Dyskinesia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.